ICE Pharma is a worldwide multinational Company specialized in natural origin Bile Acids derivates. Founded more than 60 years ago and headquartered in Reggio Emilia (Italy), the Company is now one of the main global players in natural origin bile-related products, with a network of specialist facilities and subsidiaries in Europe, Asia, Oceania, North and South America, which collect and process raw materials safely and securely. ICE’s core business includes the manufacturing of Active pharmaceutical ingredients and final dosage forms along with derivatives linked to its raw materials collection network. Its global and vertical integrated business structure allows the Company to collect raw materials and process it into ingredients, the most important of which is the Ursodeoxycholic Acid (UDCA), a key ingredient in drugs treating liver diseases and gallstones. On top of UDCA production, ICE is also committed to enhance the production of almost 20 other APIs that are currently manufactured in our sites in Italy (Reggio Emilia, Basaluzzo), India (Raichur) and New Zealand, while the FDF production is located in our site in Ivrea (Italy). ICE has 5 R&D centres, spread across Italy, United Kingdom, India and New Zealand, which allow the Company continuous growth, through the constant development in bile derivatives field as well as in innovative research and development in plant-based bile acid chemistry along with consolidated expertise in carbohydrates. ICE’s Innovation is strongly supported by cutting edge collaboration with worldwide top Universities, leading the identification of bile acid-based molecules and lead candidates for highly significant unmet diseases like Parkinson’s, Alzheimer’s, NASH. Since October 2019, ICE Group is owned by Advent International, one of the largest and most experienced global private equity investors, that started a vigorous M&A Plan in API and pharmaceutical business.